

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# 东曜药业

## TOT BIOPHARM International Company Limited

### 東曜藥業股份有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1875)**

## CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2023

This announcement is made by TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to applicable disclosure requirements of the Taipei Exchange in Taiwan, Center Laboratories, Inc. (the Company’s substantial shareholder holding over 20% of the Company’s issued share capital, whose shares are listed on the Taipei Exchange in Taiwan) is required to disclose, on a date which is expected to be on or before 15 May 2023, certain unaudited consolidated financial information of the Group for the three months ended 31 March 2023.

In order to facilitate timely dissemination of information to investors and potential investors in Hong Kong and Taiwan, the Company’s board of directors (the “**Board**”) would like to inform the Company’s shareholders and potential investors of the following unaudited consolidated financial information of the Group for the three months ended 31 March 2023, which is extracted from the Group’s latest unaudited management accounts and other information currently available.

### IMPORTANT

**As mentioned above, the Group’s results for the three months ended 31 March 2023 set out in this announcement are unaudited. The Group’s results of operations in the past have fluctuated and may in the future continue to fluctuate from one period to another period. Accordingly, the Group’s results of operations for any period should not be considered to be indicative of the results to be expected for any future period. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.**

**During the three months ended 31 March 2023, the Group’s revenue increased by 65% year-on-year to RMB132,632 thousand, mainly attributable to the substantial increase in sales of self-developed products and the expansion of CDMO/CMO business. The Group’s net loss increased year-on-year from RMB4,713 thousand to RMB16,376 thousand, mainly due to the Group’s recognition of revenue from licenses granted based on milestone achievements in the same period of 2022, while there was no such revenue in the same period of 2023.**

## CONDENSED CONSOLIDATED BALANCE SHEET

	As at 31 March 2023 RMB'000 (unaudited)	As at 31 December 2022 RMB'000 (audited)
Current assets	622,819	676,797
Non-current assets	634,380	585,234
Current liabilities	(262,291)	(275,347)
Non-current liabilities	(294,890)	(271,245)
Total net assets	<u>700,018</u>	<u>715,439</u>

## CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

	For the period from 1 January 2023 to 31 March 2023 RMB'000 (unaudited)	For the period from 1 January 2022 to 31 March 2022 RMB'000 (unaudited)
Revenue	132,632	80,249
Net loss	(16,376)	(4,713)
Loss for the period and attributable to the equity holders of the Company	(16,376)	(4,713)
Other comprehensive (loss)/income	(1,109)	304
Total comprehensive loss for the period	<u>(17,485)</u>	<u>(4,409)</u>

The above information is subject to possible adjustments following further internal review, and is not based on any figure(s) or information which has/have been reviewed by the Company's external auditor or the Audit and Connected Transactions Review Committee.

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 11 May 2023

*As at the date of this announcement, the executive director of the Company is Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Ms. Yeh-Huang, Chun-Ying and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.*